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We compared the time constant (𝜏?̇? O2) of the fundamental phase of pulmonary oxygen 24 
uptake (?̇?O2) kinetics between young adult males with type 1 diabetes and healthy controls. 25 
We also assessed the impact of priming exercise on 𝜏?̇? O2, critical power, and muscle 26 
deoxygenation in a subset of participants with type 1 diabetes. 17 males with type 1 diabetes 27 
and 17 healthy male controls performed moderate-intensity exercise to determine 𝜏?̇?O2. A 28 
subset of 7 participants with type 1 diabetes performed an additional eight visits, whereby 29 
critical power, 𝜏?̇? O2 and muscle deoxyhaemoglobin + myoglobin ([HHb+Mb]; via near-30 
infrared spectroscopy) kinetics (described by a time constant, τ[HHb+Mb]) were determined with 31 
(PRI) and without (CON) a prior 6-minute bout of heavy exercise. 𝜏?̇? O2 was greater in 32 
participants with type 1 diabetes compared to controls (type 1 diabetes: 50±13 vs. control: 33 
32±12 s; P<0.001). Critical power was greater in PRI compared to CON (PRI: 161±25 W vs. 34 
CON: 149±22 W; P<0.001), whereas 𝜏?̇?O2 (PRI: 36±15 vs. CON: 50±21 s; P=0.006) and τ[HHb+Mb] 35 
(PRI: 10±5 vs. CON: 17±11 s; P=0.037) were reduced in PRI compared to CON. Type 1 diabetes 36 
patients showed slower pulmonary ?̇? O2 kinetics when compared to controls; priming 37 
exercise speeded ?̇?O2 and [HHb + Mb] kinetics, and increased critical power in a subgroup 38 
with type 1 diabetes. These data therefore represent the first characterisation of the power-39 
duration relationship in type 1 diabetes, and the first experimental evidence that 𝜏?̇?O2 is an 40 
independent determinant of critical power in this population. 41 
Trial Registry Number: NCT03285386    42 
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1/T, linear power-inverse of time model; ANOVA, analysis of variance; 𝐴?̇?𝑂2 , amplitude of the 47 
fundamental oxygen uptake response; A[HHb+Mb], amplitude of the muscle [deoxyhaemoglobin 48 
+ deoxymyoglobin] response; BMI, body mass index; CON, control; Cr, creatine; GET, gas 49 
exchange threshold; [HbO2 + MbO2], [oxyhaemoglobin + oxymyoglobin]; [HHb + Mb], 50 
[deoxygenated haemoglobin + myoglobin]; [L-], blood [lactate]; MRT, mean response time; 51 
NIRS, near-infrared spectroscopy; PA-R, physical activity rating scale; PCr, phosphocreatine; 52 
PFA, perceived functional ability; PRI, priming condition; P-T, hyperbolic power-time model; 53 
SD, standard deviation; TD[HHb + Mb], time delay before the onset of the rise in muscle 54 
[deoxyhaemoglobin + deoxymyoglobin]; 𝑇𝐷𝑆𝐶𝑉̇ 𝑂2, time delay before the onset of the oxygen 55 
uptake slow component; [THb + Mb], [total haemoglobin + myoglobin]; ?̇?O2, oxygen uptake; 56 
?̇? O2 (b), baseline oxygen uptake; WR1-WR4, constant work rate trials used to determine 57 
critical power and W’; W-T, linear work-time model; τ[HHb+Mb], time constant for the increase 58 
in muscle [deoxyhaemoglobin + deoxymyoglobin] kinetics;  𝜏?̇? O2, time constant for the 59 










NEW & NOTEWORTHY 68 
Patients with type 1 diabetes demonstrated slower ?̇?O2 kinetics when compared to healthy 69 
controls. Furthermore, a prior bout of high-intensity exercise speeded ?̇? O2 kinetics and 70 
increased critical power in people with type 1 diabetes. Prior exercise speeded muscle 71 
deoxygenation kinetics, indicating that ?̇?O2 kinetics in type 1 diabetes are limited primarily 72 
by oxygen extraction and/or intracellular factors. These findings highlight the potential for 73 
















People with type 1 diabetes have an elevated risk of cardiovascular disease and shorter life 88 
expectancy (46, 69). Consequently, individuals with type 1 diabetes are recommended to 89 
engage in regular exercise (16), which reduces cardiovascular disease risk via improvements 90 
in glycaemic control, blood lipid profile and endothelial function (14). However, there is 91 
evidence that exercise tolerance is impaired in individuals with type 1 diabetes (34–36, 44, 45, 92 
60, 64), which is itself a barrier to exercise training (10) as well as a potent predictor of 93 
cardiovascular and overall mortality (55). Despite the importance of regular exercise in the 94 
management of type 1 diabetes, the mechanism(s) of impaired exercise tolerance observed 95 
in this population remains unknown.  96 
The capacity to tolerate high-intensity exercise is described by a hyperbolic function 97 
of external power output, defined by two parameters: critical power and W ’(40, 51, 52, 62). 98 
Critical power represents the asymptote of this relationship, whereas W’ is a finite work 99 
capacity available above critical power (40, 51, 52, 62). Critical power corresponds to the 100 
highest work rate that can be sustained without progressive contributions from non-oxidative 101 
metabolism (2, 15), and is thus fundamental to exercise tolerance. Despite the importance of 102 
critical power in determining exercise tolerance, its physiological antecedents have previously 103 
remained poorly understood.  However, data from our laboratory has shown in healthy 104 
individuals that critical power, and by extension exercise tolerance, is determined by the rate 105 
of increase in pulmonary oxygen uptake (?̇?O2, a proxy for muscle ?̇?O2 kinetics, 26) at the 106 
onset of exercise (24–28), specifically the fundamental phase time constant (𝜏?̇?O2).  107 
Despite the importance of ?̇?O2 kinetics in determining exercise tolerance (24–27), 108 
their high prognostic value (63), and the finding that exercise tolerance may be impaired in 109 
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type 1 diabetes (34–36, 44, 45, 60, 64), no previous study has assessed ?̇?O2 kinetics and/or 110 
critical power in adults with type 1 diabetes. The first hypothesis of the present study was 111 
therefore that ?̇?O2 kinetics would be slower in individuals with type 1 diabetes compared to 112 
a group of healthy controls similar for age- and physical activity status. 113 
Slowed ?̇? O2 kinetics are typically due to derangements in O2 delivery and/or O2 114 
utilisation (65). Consequently, a prior bout of heavy-intensity priming exercise (i.e. a bout of 115 
exercise below critical power but above the lactate threshold performed prior to subsequent 116 
exercise), which improves O2 delivery and intracellular O2 utilisation during subsequent 117 
exercise (22, 31, 32, 39), has been demonstrated to speed ?̇?O2 kinetics in healthy individuals 118 
with slow ?̇?O2 kinetics but without type 1 diabetes (8, 33, 66). Given the potential for slowed 119 
?̇?O2 kinetics in individuals with type 1 diabetes, as implied by their poor exercise tolerance, 120 
priming exercise may speed the ?̇?O2 kinetics (i.e. reduce 𝜏?̇?O2) and increase critical power in 121 
this population. Therefore, the second hypothesis of the present study was that priming 122 
exercise would speed pulmonary ?̇?O2 kinetics and increase critical power in individuals with 123 
type 1 diabetes. In both cases, muscle deoxygenation was non-invasively assessed via 124 
continuous interrogation of the exercising muscle via near-infrared spectroscopy (NIRS) to 125 
assess the relative importance of O2 supply and demand in determining ?̇?O2kinetics. 126 
METHODS 127 
Ethical approval 128 
This study was conducted in two parts. Part 1 compared pulmonary ?̇?O2 kinetics between a 129 
group of recreationally active males with type 1 diabetes with a group of controls similar in 130 
age- and physical activity status. Part 2 investigated the influence of priming exercise on 131 
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pulmonary ?̇?O2 kinetics and critical power in a subgroup of males with type 1 diabetes. Both 132 
studies were conducted according to the Declaration of Helsinki and all procedures were 133 
approved by the National Health Services Research Ethics Committee. All participants 134 
provided written informed consent to participate in this study.  135 
Participants  136 
In Part 1, 17 males with type 1 diabetes and 17 healthy males without type 1 diabetes similar 137 
for age, BMI and level of physical activity (Table 1) gave written informed consent to take part. 138 
Participants with type 1 diabetes were free from any diabetes complications and were not 139 
taking any medications other than insulin. No participant in either group smoked. Participants 140 
with type 1 diabetes were recruited from the diabetes outpatient clinics at the Royal Liverpool 141 
and Broadgreen University Hospitals NHS Trust. Control participants were recruited from the 142 
university and general populations. Part 2 used a subgroup of 7 males with type 1 diabetes 143 
that participated in Part 1. For the type 1 diabetes group, the following exclusion criteria were 144 
employed: 1) history of stroke, congestive heart failure, hypertension, or cardiopulmonary 145 
disease, 2) current smoking or smoking within the last 12 months, 3) autonomic or distal 146 
neuropathy, 4) HbA1c > 9.0%, 5) hypoglycaemia unawareness or 6) taking any medications 147 
other than insulin.  148 
Pre-exercise safety procedures  149 
Exercise only commenced when blood glucose concentrations were between 7-12 mmol.L-1 150 
(mg/100mL) (57). When pre-exercise blood glucose concentrations were >12 mmol.L-1, 151 
testing was either abandoned or delayed until blood glucose concentration was between 7-152 
12 mmol.L-1. When pre-exercise blood glucose concentration was <7 mmol.L-1, participants 153 
ingested ~30 g simple carbohydrates to bring blood glucose levels back to within the desired 154 
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range before exercise commenced (57). Dextrose tablets were freely available throughout 155 
testing in the case of a precipitous drop in blood glucose concentration. In addition, 156 
participants were told to make pre-exercise adjustments to their insulin dosing regimen in 157 
line their usual practice and current guidelines (57). 158 
General experimental procedures.  159 
Participants visited the laboratory on 2 (Part 1) or 10 (Part 2) separate occasions over a 2-8-160 
week period. Each test was scheduled at the same time of day (±2 h) with at least 24 h 161 
separating visits. Participants were instructed to avoid alcohol and strenuous exercise within 162 
the 24 h preceding each exercise test and not to consume caffeine within the preceding 6 h. 163 
Prior to Visit 1, each participant completed the Physical Activity Rating Scale (PA-R) and a 164 
Perceived Functional Ability (PFA) questionnaire (23). Participants were also asked to record 165 
their 24 h dietary intake and were asked to replicate this in the 24 h preceding each 166 
subsequent visit. Testing was conducted in a well-ventilated laboratory maintained between 167 
18-21oC. All exercise tests were performed on an electronically braked cycle ergometer (Lode 168 
Excalibur Sport, Groningen, The Netherlands). Saddle height/angle and handlebar 169 
height/angle were recorded at the first test and replicated for subsequent visits. During the 170 
first trial, participants were instructed to cycle at a self-selected cadence between 70-90 171 
rev/min (which was recorded and replicated in each subsequent visit). Strong verbal 172 
encouragement was provided during all exhaustive tests. Task failure was defined as the point 173 
at which cadence dropped below 50 rev/min and was recorded to the nearest second. 174 
Experimental procedures – Part 1  175 
Participants visited the laboratory on two separate occasions during Part 1. Height and weight 176 
were recorded upon arrival to the laboratory in Visit 1. Participants then undertook an 177 
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incremental ramp test until the limit of tolerance to establish ?̇? O2 peak, gas exchange 178 
threshold (GET, a non-invasive estimate of the lactate threshold), and the power output for 179 
the subsequent visit. The exercise test consisted of 3-minutes of baseline pedalling at 30 W, 180 
followed by a continuous, ramped increase in work rate of either 20 (n = 5 for both groups) 181 
or 25 W.min-1 (n = 12 for both groups) until task failure. Selection of the ramp rate for each 182 
individual participant was made based on the participant’s physical characteristics and self-183 
reported physical activity levels. Ventilatory and gas exchange variables were measured 184 
continuously breath-by-breath throughout each test. ?̇?O2 peak was defined as the final 30 s 185 
average value recorded during the test. The GET was estimated via visual procedures as 186 
previously described (24). The mean response time (MRT) for ?̇?O2 was defined as the time 187 
between the beginning of the ramp test and intersection between baseline ?̇?O2 (average 188 
?̇?O2 measured during last 30 s of baseline; ?̇?O2b) and backwards extrapolation of the ?̇?O2-189 
time relationship (7). The MRT was then utilised to calculate the power output equivalent to 190 
a given ?̇?O2 for all subsequent visits (including Part 2). Capillary blood samples were obtained 191 
at rest, immediately prior to the onset of the ramp test (i.e. final 30 s of baseline pedalling), 192 
and immediately following exhaustion. Capillary blood samples were analysed for blood 193 
glucose concentration using a portable analyser (Accutrend Plus, Roche Diagnostics, 194 
Switzerland) and blood lactate concentration ([L-]) was determined using a Biosen lactate 195 
analyser (Biosen C-Line, EKF, Germany).   196 
In Visit 2, participants performed 3 minutes of baseline pedalling at 20 W immediately 197 
before undertaking four successive 6-minute bouts of moderate-intensity exercise (i.e. below 198 
the GET) at a work rate corresponding to 70% GET, each separated by 10 minutes of pedalling 199 
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at 20 W. Capillary blood samples were obtained at rest, and 30 seconds prior to each 200 
transition to 70% GET.  201 
Experimental procedures – Part 2. 202 
 Part 2 featured eight additional visits for 7 participants with type 1 diabetes who took part 203 
in Part 1. During these visits participants were required to exercise to task failure at four fixed 204 
severe-intensity (i.e. above critical power) power outputs on two separate occasions.  The 205 
goal of this range of power outputs was to produce exercise tolerance times between 2-15 206 
minutes. These power outputs are subsequently referred to as WR1, WR2, WR3, and WR4, 207 
with WR1 being the lower and WR4 being the highest power outputs, respectively. Each 208 
exercise intensity was performed once with priming exercise (PRI) and once without priming 209 
exercise (CON). CON consisted of 3 minutes of baseline pedalling at 20 W, after which a rapid 210 
(<1 s) step increase to the required power output was abruptly applied, and participants 211 
exercised until task failure. In PRI, participants performed 3 minutes of baseline pedalling at 212 
20 W before a rapid step increase to a power output of 20%Δ (i.e. [20% of the difference 213 
between GET and ?̇?O2 peak] + GET) for 6 minutes. Upon completion of this priming bout of 214 
exercise, participants rested for 7 minutes, before performing a further 3 minutes of baseline 215 
pedalling at 20 W (providing 10 minutes rest between priming and the subsequent constant 216 
work rate bouts) and subsequently, a rapid step increase to the required power output was 217 
applied until task failure was reached. For both CON and PRI, blood glucose and [L-] samples 218 
were obtained at rest, during the last minute of baseline pedalling preceding the exhaustive 219 
constant work rate bout, and immediately following task failure.  220 
Measurements.  221 
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Participants wore a silicone face mask (Hans Rudolph, Kansas, United States) with a flow 222 
sensor (Geratherm Respiratory, GmbH, Germany), which was attached in turn via a capillary 223 
line to a metabolic cart (Blue Cherry, Geratherm Respiratory, GmbH, Germany) that was used 224 
to measure pulmonary gas exchange and ventilation breath-by-breath throughout all tests. 225 
Gases of known concentration were used to calibrate gas analysers, and a 3-liter syringe (Hans 226 
Rudolph, Kansas City, MO) was used to calibrate flow sensors. 227 
During each test, continuous non-invasive measurements of muscle 228 
oxygenation/deoxygenation status were made via a frequency-domain multi-distance NIRS 229 
system (Oxiplex TS, ISS, Champaign, USA) with light-source detector separation distances of 230 
2.25 – 3.75 cm. This NIRS device provides absolute measures of underlying tissue 231 
deoxygenated ([HHb + Mb]), oxygenated ([HbO2 + MbO2]) and total ([THb + Mb]) haemoglobin 232 
+ myoglobin concentration. The flexible NIRS probe was held firmly in place longitudinally 233 
along the belly of the right vastus lateralis muscle midway between the greater trochanter 234 
and the lateral condyle of the tibia. The NIRS probe was calibrated prior to each testing 235 
session using a calibration block of known absorption and scattering coefficients. Calibration 236 
was then cross-checked using a second block of known but distinctly different absorption and 237 
scattering coefficients. To account for the influence of adipose tissue thickness on the NIRS 238 
signal, we employed a previously employed correction factor (9, 17) to facilitate between-239 
group comparisons. Adipose tissue thickness was measured using skinfold callipers 240 
(Harpenden Skinfold Caliper, Baty International, UK). 241 
Data analysis.  242 
The breath-by-breath ?̇?O2 data from each exercise bout were examined to exclude errant 243 
breaths >4 standard deviations (SD) from the local 5-breath mean. Edited ?̇?O2 data were then 244 
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linearly interpolated to provide second-by-second values. The ?̇?O2 and [HHb + Mb] data from 245 
the four moderate transitions (Part 1) and the four bouts of heavy priming exercise (Part 2) 246 
were then time-aligned and ensemble averaged to produce a single dataset. The severe-247 
intensity criterion bouts for the determination of critical power and W’ in each condition were 248 
not repeated, hence the ?̇? O2 and [HHb + Mb] data from each of these were modelled 249 
independently (Part 2). The following monoexponential model with time delay (Eq. 1) was 250 
then used to fit the ?̇?O2 and [HHb + Mb] data: 251 
(1)   Y(t) = Y(b) + AY * (1 – e – (t – TD/ τ)) 252 
 253 
Where Y(t) is the value of the independent variable at time t, Y(b) is the baseline value 254 
measured over the final 30 seconds of baseline pedalling, AY is the amplitude of increase in Y 255 
above baseline, TD is the time delay and τ is the time constant of the response.  256 
For ?̇?O2, the first 20 s of data (i.e. representative of the “cardiodynamic” phase) were 257 
removed before modelling. During moderate exercise, data from the entirety of the 6-minute 258 
exercise bout were modelled. For heavy and severe exercise, a ?̇?O2 slow component occurs 259 
which delays the onset of a steady-state, and if not accounted for obscures the precise 260 
modelling of the fundamental phase of ?̇?O2 kinetics. Therefore, during the modelling process 261 
the fundamental phase was isolated from the time of onset of the ?̇?O2 slow component 262 
( 𝑇𝐷𝑆𝐶𝑉̇ 𝑂2 ).  This was achieved by progressively increasing the fitting window in 1-s 263 
increments to end-exercise and observing the modelled value of 𝜏?̇?O2 and χ
2 each time.  The 264 
time point at which a departure from “flatness” in the plot of 𝜏?̇?O2 and/or χ
2 versus time 265 
occurred was taken as 𝑇𝐷𝑆𝐶𝑉̇ 𝑂2, thus providing the fitting window for defining the values of 266 
the fundamental phase parameters. The amplitude of the ?̇? O2 slow component was 267 
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determined by calculating the difference between the end exercise ?̇?O2 (i.e. mean ?̇?O2 over 268 
final 30 s of exercise) and 𝐴?̇?𝑂2+?̇?O2 (b). The functional gain of the fundamental ?̇?O2 response 269 
was also calculated by dividing 𝐴?̇?𝑂2  by the change in work rate (i.e. 𝐴?̇?𝑂2/Δ work rate).  270 
For [HHb + Mb], data preceding the time point at which the [HHb + Mb] signal 271 
increased above 1 SD of the pre-transition baseline value were removed. On occasions where 272 
[HHb + Mb] decreased after exercise onset, data preceding the first point showing a sustained 273 
increase in [HHb + Mb] were removed from the modelling process. Although [HHb + Mb] data 274 
were modelled with TD allowed to vary freely such that the fit could be optimised, the point 275 
at which [HHb + Mb] began to increase is presented as TD[HHb + Mb] this is the more 276 
physiologically relevant parameter. For [HHb + Mb] during moderate exercise, the model 277 
fitting window was constrained to 120 seconds. For [HHb + Mb] during heavy and severe 278 
exercise, the model fitting window was constrained to 𝑇𝐷𝑆𝐶𝑉̇ 𝑂2. The amplitude of the [HHb 279 
+ Mb] slow component was calculated by subtracting the average value of [HHb + Mb] during 280 
the final 30 s of exercise from the absolute [HHb + Mb] response (i.e. [HHb + Mb](b) + A[HHb+Mb]).  281 
The mean values for [HbO2 + MbO2] and [THb + Mb] were determined at baseline (30 s 282 
preceding each transition), at 30 s and 120 s into the exercise transition (15 s bin centred on 283 
30 and 120 s), and at end exercise (final 30 s) to facilitate comparisons between conditions. 284 
These particular time points were chosen to allow comparisons between conditions early in 285 
the transition during the phase II increase in ?̇? O2 before the onset of the ?̇? O2 slow 286 
component and after the ?̇?O2 slow component had developed fully (i.e. at task failure).  287 
In Part 2, critical power and W’ were estimated from the time-to-task-failure and 288 
power data using three models: the hyperbolic power-time (P-T) model (Equation 4); the 289 
linear work-time (W-T) model, where the total work done is plotted against time (Equation 290 
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5); and the linear inverse-of-time (1/T) model (Equation 6), where power output is plotted 291 
against the inverse of time:  292 
(3)     P = W’ / T + CP         293 
(4)     W = CP * T + W’       294 
(5)     P = W’ * (1/T) + CP     295 
The standard errors of the estimates (SEE) associated with CP and W’ were expressed as a 296 
coefficient of variation (CV) relative to the parameter estimate. The model with the lowest 297 
average CV across conditions for each individual was then used for all subsequent analyses.  298 
Statistical analyses.  299 
In Part 1, descriptive variables, data from the ramp incremental test and kinetic parameters 300 
were compared between groups using independent samples t-tests. Differences in [HbO2 + 301 
Mb] and [THb + Mb] between groups were compared via a mixed model ANOVA. In Part 2, 302 
two-way (condition * work rate) analyses of variance (ANOVA) were used to compare 303 
differences in all kinetic parameters (i.e. ?̇?O2 and [HHb + Mb]); whereas three-way (condition 304 
* work rate * time) ANOVAs were used to compare differences in blood [L-], [glucose], [HbO2 305 
+ MbO2], and [THb + Mb]. Bonferroni-corrected pairwise comparisons were used to locate 306 
any significant main or interaction effects. Student’s paired t tests were used to compare 307 
differences in critical power and W’ between conditions. All data are presented as mean ± SD 308 
unless otherwise stated. For clarity, and to highlight values for parameters measured across 309 
all four severe-intensity work rates, the overall mean across work rates ± SD is presented in 310 
text, with work rate-specific mean ± SD presented in tables. All statistical analyses were 311 
performed in SPSS (IBM, New York, USA). Statistical significance was accepted at p < 0.05. 312 
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RESULTS  313 
Part 1.  314 
The groups did not differ for any descriptive, anthropometric, or physical activity-related 315 
variable (Table 1, all p > 0.05). ?̇?O2 peak relative to body mass (type 1 diabetes: 36.4 ± 4.7, 316 
controls: 41.4 ± 8.7 ml.kg-1.min-1, p = 0.045), the peak power attained during the ramp test 317 
normalised for body mass (type 1 diabetes: 3.3 ± 0.4, controls: 3.7 ± 0.7 W.kg-1, p = 0.038), 318 
and the GET relative to body mass (type 1 diabetes: 19 ± 2, controls: 22 ± 3 ml.kg-1.min-1, p = 319 
0.022) were lower in the type 1 diabetes group when compared to the control group (Table 320 
1).  321 
Parameters of the ?̇?O2 kinetics are presented in Table 2, whereas the group mean 322 
?̇? O2 responses are depicted in Figure 1. 𝜏?̇? O2 was greater in the type 1 diabetes group 323 
compared to the controls (type 1 diabetes: 50 ± 13 s, controls: 32 ± 12 s, p < 0.001). There 324 
were no differences with respect to any other parameter of the ?̇?O2 kinetics (Table 2).  325 
The parameters of the [HHb + Mb] kinetics are presented in Table 3, whereas the 326 
group mean [HHb + Mb] responses are depicted in Figure 2. τ[HHb+Mb] was greater (type 1 327 
diabetes: 22 ± 15, controls: 12 ± 6 seconds, p = 0.017) whereas TD[HHb+Mb] was shorter in the 328 
group with type 1 diabetes when compared to the controls (type 1 diabetes: 10 ± 4, controls: 329 
17 ± 5 seconds, p < 0.001). No other parameter of the [HHb + Mb] kinetics differed between 330 
groups (Table 3). There were no differences between groups with respect to [HbO2 + Mb] and 331 
[THb + Mb] (all comparisons p > 0.05). 332 
Part 2. 333 
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 Participant characteristics from Part 2 are reported in Table 1. Priming exercise was 334 
conducted at an average intensity of 111 ± 25 W (19 ± 12 %Δ), and resulted in an elevated 335 
blood [L-] immediately prior to the exhaustive constant work rate trials when compared to 336 
CON (CON = 1.63 ± 0.32 vs. PRI = 4.18 ± 1.19 mmol.L-1, p = 0.001) with no differences in end-337 
exercise blood [L-] (CON = 11.8 ± 2.5 vs. PRI = 11.6 ± 2.4 mmol.L-1, p = 0.576).  𝜏?̇? O2 338 
determined from the four ensemble-averaged heavy intensity bouts of priming exercise was 339 
51 ± 14 seconds.  340 
For each participant, the V̇O2 peak obtained in the incremental tests did not differ 341 
from that obtained in the constant work rate trials by more than 3%, confirming true 342 
attainment of V̇O2 max (61; Figure 3). The group mean ?̇?O2 responses to severe exercise at 343 
a representative work rate in each condition are presented in Figure 4. 𝜏?̇?O2 was smaller in 344 
PRI compared to CON (CON = 50 ± 21 vs. PRI = 36 ± 15 seconds, p = 0.006), however there 345 
were no differences between conditions for any other parameters of the ?̇?O2 kinetics (Table 346 
4).  347 
Individual fit optimisation resulted in the W-T model being used for 5 participants, the 348 
1/T model being used for 1 participant, and the hyperbolic P-T model for 1 participant. Critical 349 
power was greater in PRI when compared to CON (CON = 149 ± 22 W, CV = 2 ± 1% vs. PRI = 350 
161 ± 25 W, CV = 2 ± 1%; p < 0.001, Figure 5), whereas W’ was reduced in PRI compared to 351 
CON (CON = 16.5 ± 5.2 kJ, CV = 6 ± 3 % vs. PRI = 13.6 ± 3.5 kJ, CV = 7 ± 2 %; p = 0.024). 352 
The group mean [HHb + Mb] responses to exercise at a representative work rate in each 353 
condition are depicted in Figure 6. τ[HHb + Mb] was reduced in PRI compared to CON (CON: 17 ± 354 
11 s vs. PRI: 10 ± 5; p = 0.037), however there were no other differences with respect to any 355 
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parameters of the [HHb + Mb] kinetics. [HbO2 + MbO2] and [THb + Mb] did not differ 356 
significantly between conditions (both p > 0.05).  357 
DISCUSSION 358 
This study demonstrates that type 1 diabetes is characterised by a marked slowing of ?̇?O2 359 
kinetics, compared to healthy individuals similar in age and physical activity status. These 360 
findings are important because we have previously shown ?̇? O2 kinetics to be a central 361 
determinant of critical power, and thus exercise tolerance, which in turn is strongly related to 362 
prognosis and clinical outcomes (63). In addition to impairments to ?̇?O2 peak and the GET 363 
that have been demonstrated previously (34–36, 44, 45, 60, 64) therefore, these data suggest 364 
that slow ?̇?O2 kinetics are contributory to impaired exercise tolerance in type 1 diabetes. 365 
Moreover, and consistent with our hypotheses, we also found that “priming” exercise 366 
resulted in faster ?̇?O2 kinetics and a greater critical power when compared to the control 367 
condition. These data therefore represent the first characterisation of the power-duration 368 
relationship in type 1 diabetes, and the first experimental evidence that 𝜏?̇? O2 is an 369 
independent determinant of critical power in this population.  370 
Central to the interpretation of the data in Part 1 the present study is the degree to 371 
which the two groups were matched for possible confounding variables, such as age, physical 372 
activity status, and BMI. In this respect, it was endeavoured to match the participants for 373 
these variables between groups on an individual basis, and the averages for age, BMI, and 374 
physical activity were not different between the groups (Table 1). Furthermore, the 375 
recruitment of participants with any history of comorbidities and complications, 376 
cardiovascular or otherwise, was specifically avoided. Collectively, these precautions permit 377 
high confidence that the differences observed between groups are primarily attributable to 378 
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the presence or absence of type 1 diabetes, rather than the presence of comorbidities, 379 
reduced physical activity status or differences in age.  380 
Oxygen uptake kinetics and exercise tolerance 381 
Aerobic fitness is an important determinant of cardiovascular risk (1), and 382 
cardiovascular risk is already substantially higher in individuals with type 1 diabetes compared 383 
to individuals without diabetes (46). The findings from Part 1 are therefore clinically relevant 384 
to individuals living with type 1 diabetes, suggesting that interventions aimed at mitigating 385 
cardiovascular risk and improving life expectancy in type 1 diabetes necessitate a strong focus 386 
on improvement of aerobic fitness. The 𝜏?̇?O2 value observed in the type 1 diabetes group was 387 
~50 seconds, a value that is similar to that previously reported in healthy older adults with a 388 
mean age of 69 years (13). These findings concur with the numerical (although non-389 
significant) slowing of ?̇?O2 kinetics reported by Nadeau et al. (56) in youth with type 1 390 
diabetes. Thus, the present findings demonstrate that type 1 diabetes results in an 391 
impairment in ?̇?O2 kinetics that is equivalent to >30 years of ageing, a finding that broadly 392 
supports the recent suggestion that type 1 diabetes may be considered as a condition of 393 
accelerated muscle ageing (49).  394 
The present study (Part 2) also shows that a bout of heavy-intensity priming exercise 395 
speeded ?̇?O2 kinetics (i.e. reduced 𝜏?̇?O2) with a concomitant increase in critical power of 396 
~8% compared to the control condition. These data thus add to the growing body of evidence 397 
(24–28) that 𝜏?̇?O2 and critical power are causally related. The putative explanation given for 398 
this inverse, causal relationship between 𝜏?̇? O2 and critical power is that critical power 399 
represents the highest work rate for which the accumulation of the O2 deficit may be 400 
stabilised, and thus a metabolic steady-state attained (53, 65). 𝜏?̇?O2 determines the size of 401 
19 
 
the O2 deficit (71, 72), thus a faster ?̇?O2 response will minimise reliance on substrate level 402 
phosphorylation, in turn reducing muscle metabolic perturbation (e.g. reduced Δ[PCr], Δ[Cr], 403 
Δ[ADP], Δ[ATP]) and fatigue-related metabolite accumulation during the rest-to-exercise 404 
transition (72). The resultant effect is an increase in the highest work rate that can be attained 405 
for a given magnitude of O2 deficit accumulation, otherwise known as critical power. Since 406 
critical power is fundamental to the capacity to tolerate exercise, the increased 𝜏?̇?O2 in type 407 
1 diabetes demonstrated in part 1 therefore likely underpins the impaired exercise tolerance 408 
in this population (present study; 38, 64).    409 
Data derived from NIRS showed that the group with type 1 diabetes demonstrated a 410 
shorter TD[HHb+Mb] and greater τ[HHb+Mb], as compared to health controls (Part 1). Given the 411 
slower ?̇?O2 kinetics observed in the type 1 diabetes group, the shorter TD[HHb+Mb] is likely 412 
representative of an impairment in muscle O2 availability during the early phase (i.e. 10-20 s) 413 
of exercise. This interpretation is supported by the observation of substantially impaired 414 
muscle O2 delivery during contractions in rats with diabetes (6, 42, 67), and blunted exercise-415 
induced rises in blood volume in humans with type 1 diabetes (38). On the other hand, the 416 
greater τ[HHb+Mb] in the type 1 diabetes group likely indicates impairments to the capacity to 417 
increase intracellular O2 utilisation (i.e. muscle ?̇?O2) to an extent that is proportionally more 418 
important than any reduction in O2 delivery. Hence, the data obtained via NIRS from Part 1 419 
suggest that derangements in both muscle O2 delivery and utilisation underpin the slow ?̇?O2 420 
kinetics observed in individuals with type 1 diabetes, as compared to healthy controls.  421 
Priming exercise has the capacity to enhance both muscle O2 delivery and utilization 422 
at the onset of exercise (22, 32, 39). In Part 2, the effect of priming exercise on critical power 423 
could therefore have been via an independent effect of enhanced O2 availability, rather than 424 
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a reduced 𝜏?̇?O2 per se (28). However, the reduction in τ[HHb+Mb (i.e. muscle deoxygenation 425 
kinetics were speeded) afforded by priming exercise, alongside an unchanged TD[HHb+Mb], 426 
indicates that the salutary effect of priming exercise on ?̇?O2 kinetics and critical power were 427 
due more so to an upregulation of intracellular O2 utilisation as compared to any 428 
enhancements to O2 delivery. This interpretation is bolstered by the observation that in our 429 
type 1 diabetes population neither [THb + Mb] or [HbO2 + MbO2] were improved immediately 430 
before or during exercise following priming exercise. Indeed, the augmentation of the 431 
intracellular determinants of ?̇?O2 following priming exercise is well documented (22, 32, 39), 432 
and the notion that ?̇?O2 kinetics are primarily limited by intracellular oxidative metabolic 433 
inertia in type 1 diabetes is supported by several lines of evidence. For instance, biopsy data 434 
indicate that young, active individuals with type 1 diabetes demonstrate ultrastructural 435 
alterations in mitochondria that impair mitochondrial bioenergetics and reduce 436 
mitochondrial capacity despite no loss of muscle capillary density (38, 48–50), findings which 437 
are largely supported by magnetic resonance spectroscopy studies of oxidative metabolism 438 
in this population (18, 19, 41). These findings are in stark contrast to other clinical conditions 439 
such as heart failure (68), type II diabetes (5), and peripheral arterial disease (4) where ?̇?O2 440 
kinetics are limited due to impaired O2 delivery. In type 1 diabetes, therefore, our data 441 
strongly suggest that ?̇?O2 kinetics, and in turn critical power and exercise tolerance, are 442 
primarily limited by impaired intracellular (i.e. mitochondrial) utilisation of O2, rather than 443 
due to O2 delivery impairments . Furthermore, these derangements to cellular metabolism 444 
can, at least partially, be reversed via a prior bout of priming exercise, presumably via an 445 
upregulation of enzyme activation at potentially limiting sites within the oxidative respiratory 446 




Our data suggest that in type 1 diabetes, impairments to O2 utilisation are the primary 449 
limiting factor to ?̇?O2 kinetics, and by extension exercise tolerance. However, our findings do 450 
point towards impaired O2 delivery (as indicated by the reduced TD[HHb+Mb]) being contributory 451 
in the exercise intolerance observed in type 1 diabetes. Central measures of O2 availability 452 
(i.e. cardiac output, heart rate, etc.) were not included in the present study, therefore a role 453 
for impaired central O2 delivery also cannot be excluded. However, NIRS primarily monitors 454 
changes in the oxygenation status of the microvasculature (i.e. at the sites of gas exchange) 455 
and is thus likely to more closely represent the factors limiting skeletal muscle respiration in 456 
the interrogated region when compared to central measures of O2 delivery (3, 20, 21, 30). 457 
However, our NIRS measurements were conducted at a single, superficial site on the vastus 458 
lateralis, yet skeletal muscle deoxygenation (43), blood flow (37) and metabolism (11) are 459 
spatially and temporally heterogeneous during exercise. Moreover, the reductions in the 460 
number of capillaries supporting flow and red blood cell flux in animal models of both type 1 461 
(42, 67) and type 2 diabetes (58) would predict a more heterogeneous distribution of 462 
perfusion and wide range of O2 delivery-to-?̇?O2 ratios across the exercising muscle mass. This 463 
latter suggestion is supported by the notion that alterations in the endothelial glycocalyx in 464 
diabetes may result in heterogeneous microvascular perfusion (47). Hence, although we have 465 
concluded that enhancements to intracellular metabolism were primarily responsible for the 466 
faster ?̇?O2 kinetics observed following priming in the present study, it is possible that this 467 
was not the case in other, unmeasured muscular regions. Indeed a more heterogeneous 468 
matching of blood flow-to-?̇?O2 could independently account for the reduced TD[HHb + Mb] 469 
observed in the type 1 diabetes patients examined herein. Furthermore, a limitation of the 470 
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present study is that only males were studied. Female participants were excluded from the 471 
present study due to concerns that the relatively greater adiposity in females compared to 472 
males with type 1 diabetes (70) would blunt the NIRS signal. Indeed, it has recently been 473 
demonstrated that the effect of type 1 diabetes on mitochondrial bioenergetics is dependent 474 
upon sex (36). Future research should therefore determine whether females with type 1 475 
diabetes also exhibit similar impairments in key parameters of aerobic metabolism.       476 
Significance 477 
Since critical power fundamentally underpins the capacity to tolerate exercise, our findings in 478 
type 1 diabetes of impaired 𝜏?̇?O2 and causative relationship between 𝜏?̇?O2 and critical power 479 
have important implications for the development of interventions to enhance aerobic fitness 480 
in this patient group.  Indeed, our finding of impairments in each of the most important 481 
parameters of aerobic function, (i.e. ?̇?O2 peak, GET, 𝜏?̇?O2 & critical power) in type 1 diabetes 482 
supports recent suggestions that the current physical activity recommendations (16) may be 483 
insufficient to offset the deleterious effects of this disorder on aerobic function (50). An 484 
increased volume of physical activity/exercise training may therefore be required to prevent 485 
the pernicious effects of type 1 diabetes on various components of the oxidative respiratory 486 
chain, in particular the intracellular O2 utilisation pathways. Moreover, our data suggest that 487 
interventions that can specifically improve the speed of the ?̇? O2 kinetics will enhance 488 
exercise tolerance in this population. Since exercise tolerance is a potent predictor of 489 
cardiovascular risk and all-cause mortality in type 1 diabetes (12, 54, 55, 59), we may assume 490 
that improving 𝜏?̇? O2 via interventions that augment intracellular O2 utilisation and O2 491 




This study demonstrated impaired exercise tolerance and aerobic function in a group of 494 
physically active males with type 1 diabetes in moderate glycaemic control without micro- or 495 
macrovascular disease complications when compared to a group of healthy controls similar 496 
for age- and physical activity-status. This is the first assessment of ?̇?O2 kinetics in adults with 497 
type 1 diabetes, and we demonstrate a profound slowing of the ?̇?O2 kinetics (i.e. increased 498 
𝜏?̇?O2) in the type 1 diabetes group relative to the control group. The injurious effects of type 499 
1 diabetes on the aerobic phenotype noted herein are likely to contribute to the burden 500 
associated with the disease and its secondary complications. Furthermore, given the reduced 501 
𝜏?̇? O2 and concomitant increase in critical power following priming exercise in Part 2, the 502 
present data identifies for the first time the increased 𝜏?̇?O2 as being causative for the exercise 503 
intolerance inherent in type 1 diabetes. The slow [HHb + Mb] kinetics in type 1 diabetes (Part 504 
1) and subsequent speeding with priming exercise (Part 2), strongly suggest that the 505 
impairments to ?̇?O2 kinetics and exercise tolerance in type 1 diabetes are due primarily to 506 
derangements in intracellular oxidative metabolism and/or O2 extraction, rather than O2 507 
delivery. These findings highlight 𝜏?̇? O2 as a therapeutic target for interventions aimed at 508 
improving exercise tolerance and cardiovascular risk, most pertinently via repairs to 509 
intracellular metabolism and muscle O2 extraction.  510 
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Figure 1. Parameters of the ?̇? O2 kinetics for moderate-intensity exercise (70% gas 
exchange threshold) in Part 1. Type 1 diabetes group (T1D) shown as clear circles; control 
group (CON) shown as black circles.  Panel A: Individual data showing the oxygen uptake 
kinetics fundamental phase time constant values (τV̇O2) for each participant in both groups. 
Solid black line represents the group mean. * indicates significant difference between 
groups (P < 0.001). Panel B: Group mean ?̇?O2 responses to moderate exercise, with group 
mean 𝜏?̇?O2 values displayed. Error bars removed for clarity. 
Figure 2. Parameters of the muscle [HHb + Mb] kinetics for moderate exercise in Part 1. 
Type 1 diabetes group shown as clear circles; control group shown as black circles, dashed 
vertical line represents onset of exercise.  Panel A: Group mean [HHb + Mb] responses to 
moderate exercise. Panel B: Group mean [HHb + Mb] responses during the first 30 seconds 
of exercise. TD[HHb+Mb] values were significantly different between groups (P < 0.001). Panel 
C: Group mean [HHb + Mb] responses to moderate exercise, normalised as a percentage of 
the amplitude of the response, with τ[HHb+Mb] values displayed. τ[HHb+Mb] values were 
significantly different between groups (P = 0.017). 
Figure 3. V̇O2 responses to the incremental ramp test (black circles) in a representative 
participant, and V̇O2 peak values attained during the constant work rate trials used for 
determination of critical power in CON (clear circles) and PRI (black triangles).  Black 
square represents V̇O2 value attained during the final 30 s of heavy-intensity priming 
exercise. Dashed vertical lines indicate the boundaries partitioning exercise intensity 
domains, i.e. the gas exchange threshold (GET) and critical power (CP) in both CON and PRI. 
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Horizontal dashed lines represent the V̇O2 peak value attained during ramp incremental 
exercise ± 3%. Note that the V̇O2 peak values attained during ramp and constant work rate 
exercise differ by less than 3% in all cases, confirming attainment of a true V̇O2 max in all 
trials. Redrawn from Poole & Jones (61) using data from the present study. 
Figure 4. Group mean V̇O2 responses to WR 1 during the rest-to-exercise transition (panel 
A) in the control condition (black squares) and the primed condition (clear triangles) in Part 
2, normalised as a percentage of their fundamental phase amplitude. Exponential model 
fits are displayed as thick grey lines. Panel B displays the same data, however the final data 
point represents the average time to exhaustion in each condition.  
Figure 5. Critical power measured in the control (CON) and primed (PRI) conditions in Part 
2. Group mean ± SD (n = 7) are shown as open bars, and individual participant changes are 
shown as dashed black lines. * indicates significant difference between conditions (P < 
0.001). 
Figure 6. Group mean [HHb + Mb] kinetic responses to WR 1 during the rest-to-exercise 
transition in the control condition (black squares) and the primed condition in Part 2 (clear 
triangles), normalised as a percentage of the fundamental phase amplitude. Exponential 
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Table 1. Participant characteristics. 
 Part 1  Part 2 
Characteristic Control (n = 17) Type 1 diabetes (n = 17) Type 1 diabetes (n = 7) 
    
Age (years) 33 ± 15 33 ± 13 39 ± 17 
Weight (kg) 79 ± 15 78 ± 11 81 ± 8 
Height (cm) 181 ± 5 178 ± 6 179 ± 6 
BMI (kg/m2) 24.1 ± 4.1 24.7 ± 2.9 25.1 ± 2.5 
HbA1c (mmol/mol) - 56.6 ± 10.2 56.5 ± 7.7 
HbA1c (%) - 7.3 ± 0.9 7.3 ± 0.7 
Diabetes duration (years) - 15 ± 13 14 ± 17 
Diabetes diagnosis (years of age) - 18 ± 8 25 ± 10 
Physical activity rating scale score 5.1 ± 1.5 5.2 ± 2.0 5.1 ± 2.0 
Perceived functional ability score 15.7 ± 5.4 15.8 ± 4.1 15.7 ± 3.0 
Light physical activity (h/week) 1.0 ± 1.5 1.3 ± 0.9 1.4 ± 0.9 
Moderate physical activity 
(h/week) 
2.5 ± 1.4 2.0 ± 1.1 2.0 ± 1.1 
Vigorous physical activity (h/week) 1.6 ± 1.3 1.6 ± 1.2 1.7 ± 1.1 
Peak power (W) 267 ± 60 236 ± 47 246 ± 29 
Peak power (W·kg-1) 3.69 ± 0.69 3.27 ± 0.39 * 3.06 ± 0.17 
?̇?O2 peak (L.min-1) 3.24 ± 0.86 2.87 ± 0.63 2.73 ± 0.46 
?̇?O2 peak (ml·kg-1·min-1) 41.4 ± 8.7 36.4 ± 4.7 *  33.7 ± 3.4  
Gas exchange threshold (L.min-1) 1.68 ± 0.26 1.51 ± 0.24 * 1.42 ± 0.12  
Gas exchange threshold (ml.kg-
1.min-1) 
19 ± 2 22 ± 3 * 18 ± 1 
Gas exchange threshold (W) 100 ± 16 87 ± 16 * 82 ± 17  
 
Data are means ± SD, * indicates significantly different from control group (P < 0.05). Physical activity rating scale 
and perceived functional ability score are derived from questionnaires, with each being scored on scales of 1-10 
and 1-20, respectively. 
 
Table 2. Pulmonary oxygen uptake kinetics during moderate-intensity cycle exercise in Part 1. 
Parameter Control (n = 17) Type 1 diabetes (n = 17) 
?̇?O2 baseline, L.min-1 0.98 ± 0.17 0.93 ± 0.21 
𝑇𝐷?̇?𝑂2 , s 15 ± 10 12 ± 7 
𝜏?̇?O2, s 
32 ± 12 50 ± 13 * 
𝐴?̇?𝑂2, L.min
-1 
0.47 ± 0.14 0.42 ± 0.12 
Gain, ml.min-1.W-1 
9.4 ± 2.1 9.7 ± 2.1 
End-ex ?̇?O2, L.min-1 
1.44 ± 0.23 1.35 ± 0.30 
𝑇𝐷?̇?𝑂2 , fundamental time delay; 𝜏?̇?O2, fundamental time constant; 𝐴?̇?𝑂2 , fundamental amplitude; 
Gain, increase in fundamental phase ?̇?O2 per unit increase in power output; End-ex ?̇?O2, end-
exercise ?̇?O2. * indicates significantly different from the control group (P < 0.001). 
 
Table 3. Muscle deoxygenation kinetic responses to moderate-intensity cycle exercise in Part 1.  
Parameter Control (n = 17) Type 1 diabetes (n = 17) 
[HHb+Mb](b), μM 17.9 ± 9.2 21.9 ± 9.8 
TD[HHb+Mb], s 17 ± 5 10 ± 4 * 
τ[HHb+Mb], s 
12 ± 6 22 ± 15 * 
A[HHb+Mb],  μM 
5.2 ± 4.2 5.1 ± 4.5 
[HHb+Mb](b) + A[HHb+Mb],  μM 
23.0 ± 10.6 25.4 ± 14.8 
[HHb+Mb] end-ex, μM  
21.3 ± 11.8 28.3 ± 14.7 
[HHb+Mb](b), mean [HHb+Mb] over last 30 s of baseline; TD[HHb+Mb], time delay before exponential 
rise in [HHb+Mb]; τ[HHb+Mb], time constant of [HHb+Mb] response; A[HHb+Mb], amplitude of [HHb+Mb] 
response; [HHb+Mb] end-ex, mean [HHb+Mb] over last 30 seconds of exercise. * indicates 
significantly different from control (P < 0.05).  
 
Table 4. Pulmonary oxygen uptake responses to severe intensity cycle 
exercise in Part 2. 
Baseline (L.min-1) CON PRI 
WR 1 0.92 ± 0.30 1.07 ± 0.16 
WR 2 1.00 ± 0.19 0.88 ± 0.17 
WR 3 0.92 ± 0.33 0.88 ± 0.24 
WR 4 0.92 ± 0.15 0.95 ± 0.25 
TD (s)  
WR 1 14 ± 6 11 ± 7 
WR 2 12 ± 8 14 ± 11 
WR 3 13 ± 6 18 ± 10 
WR 4 5 ± 8 11 ± 7 
𝜏?̇?O2 (s)  
WR 1 53 ± 21 42 ± 19 
WR 2 48 ± 22 33 ± 14 
WR 3 49 ± 29 33 ± 12 
WR 4 50 ± 16 35 ± 13 
A  (L.min-1)   
WR 1 1.29 ± 0.33 1.23 ± 0.32 
WR 2 1.38 ± 0.41 1.46 ± 0.36 
WR 3 1.61 ± 0.33 1.51 ± 0.32 
WR 4 1.73 ± 0.38 1.54 ± 0.43 
Absolute A (L.min-1)   
WR 1 2.21 ± 0.43 2.30 ± 0.42 
WR 2 2.37 ± 0.50 2.35 ± 0.38 
WR 3 2.53 ± 0.53 2.39 ± 0.45 




WR 1 8.02 ± 1.54 7.73 ± 1.20 
WR 2 7.43 ± 1.28 8.21 ± 1.03 
WR 3 7.91 ± 0.66 7.67 ± 1.66 
WR 4 7.67 ± 0.91 7.12 ± 1.42 
SC  (L.min-1)  
WR 1 0.53 ± 0.30 0.45 ± 0.20 
WR 2 0.45 ± 0.26 0.44 ± 0.25 
WR 3 0.12 ± 0.14 0.30 ± 0.30 
* 
 WR 4 0.15 ± 0.18 0.20 ± 0.19 
End-ex  (L.min-1)  
WR 1 2.73 ± 0.52 2.75 ± 0.47 
WR 2 2.82 ± 0.43 2.78 ± 0.52 
WR 3 2.61 ± 0.59 2.67 ± 0.56 
WR 4 2.73 ± 0.51 2.71 ± 0.59 
?̇? O2, oxygen uptake; baseline, average value over final 30 s of baseline period; TD, 
fundamental time delay;  𝜏?̇?O2, fundamental time constant;  A, fundamental amplitude; 
Absolute A, baseline + fundamental amplitude; Gain, increase in fundamental phase ?̇?O2 per 
unit increase in power output;  SC, magnitude of the slow component; end-ex,  average 
value over final 30 s of exercise; CON, control condition in Part 2; PRI, primed condition in Part 
2. * indicates significant main effect of condition (P < 0.01). 
 
